{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:56:05Z","timestamp":1763423765014,"version":"3.45.0"},"reference-count":23,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Carriers of a CYP21A2 pathogenic variant exhibit distinct hormonal differences, yet their impact on assisted reproductive technology outcomes remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether carriers of a CYP21A2 pathogenic variant exhibit differences in ovarian stimulation response and in vitro fertilization outcomes compared with noncarriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective cohort study at a single, private, academic center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects<\/jats:title>\n                    <jats:p>A total of 1284 subjects undergoing 1556 in vitro fertilization cycles were ultimately included in the analysis, comprising 244 carriers and 1040 noncarrier controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Female monoallelic CYP21A2 mutation carrier status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Live birth rates following frozen single euploid embryo transfer. Secondary outcomes included ovarian stimulation parameters, embryological development (fertilization and euploidy rates), and posttransfer outcomes (implantation, clinical pregnancy, and pregnancy loss rates).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline characteristics and ovarian stimulation parameters were similar between pathogenic CYP21A2 variant carriers and noncarriers. No significant differences were observed in live birth (50.7% vs 51.1%, P = .87), implantation (75.4% vs 73.4%, P = .99), or clinical pregnancy (63.3% vs 62.7%, P = .73) rates between carriers and noncarriers, respectively. Although a univariate analysis of fertilization rates (81.7% vs 83.3%, P = .008) showed a significance difference, this difference was not observed after adjusting for confounding variables in a multivariate analysis (adjusted odds ratio of 1.05; 95% CI, 0.93-1.18).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Female patients who carry a pathogenic CYP21A2 variant achieve in vitro fertilization outcomes comparable to noncarriers. These findings support maintaining standard assisted reproductive treatment protocols for carriers and help provide personalized counseling for carriers identified through genetic screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf198","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T07:17:15Z","timestamp":1743578235000},"page":"e4169-e4175","source":"Crossref","is-referenced-by-count":0,"title":["Assisted Reproduction Technology Treatment Outcomes in Female Carriers of 21-Hydroxylase Deficiency"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-0576","authenticated-orcid":false,"given":"Arthur C","family":"Arcaz","sequence":"first","affiliation":[{"name":"Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai , New York, NY 10029 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6703-1341","authenticated-orcid":false,"given":"Carlos","family":"Hernandez-Nieto","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Associates of New York , New York, NY 10022 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A","family":"Lee","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Associates of New York , New York, NY 10022 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa A","family":"Cacchione","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Associates of New York , New York, NY 10022 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanmoy","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai , New York, NY 10029 ,","place":["USA"]},{"name":"Reproductive Medicine Associates of New York , New York, NY 10022 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan B","family":"Copperman","sequence":"additional","affiliation":[{"name":"Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai , New York, NY 10029 ,","place":["USA"]},{"name":"Reproductive Medicine Associates of New York , New York, NY 10022 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"2","key":"2025111718523688200_dgaf198-B1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.beem.2008.10.014","article-title":"Genetics of congenital adrenal hyperplasia","volume":"23","author":"Hannah-Shmouni","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2025111718523688200_dgaf198-B2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1210\/jc.2009-1383","article-title":"Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"95","author":"Bidet","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025111718523688200_dgaf198-B3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11154-022-09770-5","article-title":"The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum","volume":"24","author":"Maher","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"issue":"11","key":"2025111718523688200_dgaf198-B4","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1210\/jc.2018-01863","article-title":"Genital reconstructive surgery in females with congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"103","author":"Almasri","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025111718523688200_dgaf198-B5","first-page":"635","article-title":"Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"74","author":"Feldman","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2025111718523688200_dgaf198-B6","doi-asserted-by":"crossref","first-page":"105554","DOI":"10.1016\/j.jsbmb.2019.105554","article-title":"Clinical and hormonal characteristics in heterozygote carriers of congenital adrenal hyperplasia","volume":"198","author":"Guarnotta","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"2025111718523688200_dgaf198-B7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.14740\/jem843","article-title":"Differences in hormonal levels between heterozygous CYP21A2 pathogenic variant carriers, non-carriers, and females with non-classic congenital hyperplasia","volume":"66","author":"Silva","year":"2022","journal-title":"Arch Endocrinol Metab"},{"issue":"7","key":"2025111718523688200_dgaf198-B8","first-page":"2097","article-title":"Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"82","author":"Witchel","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025111718523688200_dgaf198-B9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4274\/jcrpe.galenos.2021.2021.0184","article-title":"17-hydroxyprogesterone response to standard dose synacthen stimulation test in CYP21A2 heterozygous carriers and non-carriers in symptomatic and asymptomatic groups: meta-analyses","volume":"14","author":"Polat","year":"2022","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"4","key":"2025111718523688200_dgaf198-B10","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.fertnstert.2019.02.106","article-title":"Nonclassical congenital adrenal hyperplasia carriers have a higher prevalence of polycystic ovarian syndrome than the general population","volume":"111","author":"Merriam","year":"2019","journal-title":"Fertil Steril"},{"issue":"10","key":"2025111718523688200_dgaf198-B11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41431-020-0653-5","article-title":"EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency","volume":"28","author":"Baumgartner-Parzer","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"2025111718523688200_dgaf198-B12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/EJE-11-0119","article-title":"Relationship of CYP21A2 genotype and serum 17-hydroxyprogesterone and cortisol levels in a large cohort of Italian children with premature pubarche","volume":"165","author":"Ghizzoni","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025111718523688200_dgaf198-B13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/09513590903511505","article-title":"Premature pubarche in Mediterranean girls: high prevalence of heterozygous CYP21 mutation carriers","volume":"26","author":"Paris","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"2025111718523688200_dgaf198-B14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fendo.2019.00432","article-title":"The complexities in genotyping of congenital adrenal hyperplasia: 21-hydroxylase deficiency","volume":"10","author":"Pignatelli","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2025111718523688200_dgaf198-B15","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/gim.2017.46","article-title":"Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians","volume":"19","author":"Hannah-Shmouni","year":"2017","journal-title":"Genet Med"},{"issue":"5","key":"2025111718523688200_dgaf198-B16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"9","key":"2025111718523688200_dgaf198-B17","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/humrep\/dez129","article-title":"What is the reproductive potential of day 7 euploid embryos?","volume":"34","author":"Hernandez-Nieto","year":"2019","journal-title":"Hum Reprod"},{"issue":"8","key":"2025111718523688200_dgaf198-B18","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/humrep\/deaa123","article-title":"Late follicular phase progesterone elevation during ovarian stimulation is not associated with decreased implantation of chromosomally screened embryos in thaw cycles","volume":"35","author":"Hernandez-Nieto","year":"2020","journal-title":"Hum Reprod"},{"issue":"9","key":"2025111718523688200_dgaf198-B19","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/humrep\/dex234","article-title":"The international glossary on infertility and fertility care, 2017","volume":"32","author":"Zegers-Hochschild","year":"2017","journal-title":"Hum Reprod"},{"issue":"4","key":"2025111718523688200_dgaf198-B20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ymgme.2006.12.005","article-title":"Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency","volume":"90","author":"Wilson","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2025111718523688200_dgaf198-B21","first-page":"479","article-title":"Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism","volume":"82","author":"Knochenhauer","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025111718523688200_dgaf198-B22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12884-018-2091-8","article-title":"Miscarriages in families with an offspring that have classic congenital adrenal hyperplasia and 21-hydroxylase deficiency","volume":"18","author":"D\u00f6rr","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"issue":"12","key":"2025111718523688200_dgaf198-B23","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1210\/jc.2019-01199","article-title":"Carriers of a classic CYP21A2 mutation have reduced mortality: a population-based national cohort study","volume":"104","author":"Nordenstr\u00f6m","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf198\/62838922\/dgaf198.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/12\/e4169\/62838922\/dgaf198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/12\/e4169\/62838922\/dgaf198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:52:47Z","timestamp":1763423567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/12\/e4169\/8103701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,4,2]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf198","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"type":"print","value":"0021-972X"},{"type":"electronic","value":"1945-7197"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,4,2]]}}}